Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BYOGRAYZ
- Development stage
- Unknown
- Lead developer
- Humanetics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BYOGRAYZ (BIO 300) is an orally administered, patented nanosuspension formulation of genistein developed by Humanetics Corporation. It is designed as a prophylactic medical countermeasure (MCM) to protect military personnel, first responders, and cancer patients from the toxic effects of ionizing radiation. The drug acts as a radiation modulator by inducing a reversible G2/M cell cycle arrest in susceptible cells, thereby providing a window of protection during radiation exposure. Additionally, it exhibits antioxidant and anti-inflammatory properties. BYOGRAYZ is currently being evaluated in clinical trials for the prevention of Acute Radiation Syndrome (ARS) and for mitigating radiation-induced lung injury in patients with non-small cell lung cancer (NSCLC), as well as for treating lung injury associated with COVID-19.
- Brand names
- BYOGRAYZBYOGRAYS
- Other names
- genistein nanosuspensiongenistein
02
Targets
ESR2 (ERβ)PTK (Protein-Tyrosine Kinase)
Beyond the preview
Go deeper on BYOGRAYZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BYOGRAYZ.